Neuroendocrine Tumors: Current Recommendations for Diagnosis and Surgical Management

Endocrinology and Metabolism Clinics of North America

Volumn 40, Issue 1, 2011, Pages 205-231

  Joseph, Saju ^a   Wang, Yi Zarn ^a   Boudreaux, J Philip ^a   Anthony, Lowell B ^a   Campeau, Richard ^a   Raines, Daniel ^a   O'Dorisio, Thomas ^b   Go, Vay Liang ^c   Vinik, Aaron I ^d   Cundiff, Jason ^a   Woltering, Eugene A ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Biochemical markers; Chemotherapy; Foregut; Hindgut; Imaging; Midgut; Neuroendocrine tumors; Radiation therapy; Surgery; Tumor markers

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ALPHA INTERFERON; ANGIOPEPTIN; CHROMOGRANIN A; CHROMOGRANIN B; DOXORUBICIN; FLUOROURACIL; INTERFERON; IODINATED POPPYSEED OIL; LONG ACTING DRUG; LUTETIUM 177; MITOMYCIN C; OCTREOTIDE; PANCREASTATIN; SEROTONIN; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; YTTRIUM 90;

CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOID; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DISEASE MARKER; DRUG EFFICACY; DRUG HALF LIFE; DRUG TREATMENT FAILURE; ENDOSCOPIC ECHOGRAPHY; HUMAN; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SEROTONIN BLOOD LEVEL; SEROTONIN RELEASE; TREATMENT RESPONSE; TUMOR CLASSIFICATION; TUMOR LOCALIZATION; VERNER MORRISON SYNDROME;

3-IODOBENZYLGUANIDINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; GASTROINTESTINAL NEOPLASMS; HUMANS; IODINE RADIOISOTOPES; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; SOMATOSTATIN; TUMOR MARKERS, BIOLOGICAL;

EID: 79951734388     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2010.08.004     Document Type: Review

References (40)

1. Kloppel G., Perren A., Heitz P.U. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification [abstract]. Ann N Y Acad Sci 2004, 1014:13-27.
2. Plockinger U., Rindi G., Arnold R., et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumors. A consensus statement on behalf of the European Neuroendocrine Tumor Society (ENETS). Neuroendocrinology 2004, 80:394-424.
3. Woltering E.A., Hilton R.S., Zolfoghary C.M., et al. Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency. Pancreas 2006, 33(3):250-254.
4. Nakakura E.K., Venook A.P., Bergsland E.K. Systemic and regional nonsurgical therapy: what is the optimal strategy for metastatic neuroendocrine cancer?. Surg Oncol Clin N Am 2007, 16(3):639-651.
5. Sundin A., Vullierme M.P., Kaltsas G., et al. ENETS guidelines for the standard of care in patients with neuroendocrine tumours: radiological examination in patients with neuroendocrine tumours. Neuroendocrinology 2009, 90:167-183.
6. Oberg K., Ferone D., Kaltsas G., et al. ENETS guidelines for the standard of care in patients with neuroendocrine tumours: biotherapy. Neuroendocrinology 2009, 90:209-213.
7. Ramage J.K., Davies A.H., Ardill J., et al. Guidelines for the management of gastro-enteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005, 54(Suppl 4):1-16.
8. Godwin J.D. Carcinoid tumors. An analysis of 2,837 cases. Cancer 1975, 36:560-569.
9. Calhoun K., Toth-Fejel S., Cheek J., et al. Serum peptide profiles in patients with carcinoid tumors. Am J Surg 2003, 186(1):28-31.
10. Udupi V., Lee H.M., Kurosky A., et al. Prohormone convertase-1 is essential for conversion of chromogranin A to pancreastatin. Regul Pept 1999, 83(2-3):123-127.
11. Niederhuber J.E., Fojo T. Treatment of metastatic disease in patients with neuroendocrine tumors. Surg Oncol Clin N Am 2006, 15:511-533.
12. Oberg K., Astrup L., Eriksson B., et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II - specific NE tumour Types. Acta Oncol 2004, 43(7):626-636.
13. Morton K.M., Kamel I., Hofmann L., et al. Carcinoid tumors of the small bowel: a multitechnique imaging approach. AJR Am J Roentgenol 2004, 182:559-567.
14. Graham G.W., Unger B.P., Coursin D.B. Perioperative management of selected endocrine disorders. Int Anesthesiol Clin 2000, 38:31-67.
15. Woltering E.A., Mamikunian P.M., Zietz S., et al. Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors. Pancreas 2005, 31:392-400.
16. Woltering E.A., Salvo V.A., O'Dorisio T.M., et al. Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients. Pancreas 2008, 37(1):94-100.
17. Luo Q., Peyman G.A., Conway M.D., et al. Effect of a somatostatin analog (octreotide acetate) on the growth of retinal pigment epithelial cells in culture. Curr Eye Res 1996, 15(9):909-913.
18. Ducrux M., Ruszniewski P., Chayvialle J.A. The antitumoral effect of the long acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000, 95:3276-3281.
19. Rinke A., Muller H.H., Schade-Brittinger C., et al. Placebo-controlled, double blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 2009, 27(28):4635-4636.
20. Mozell E., Woltering E.A., O'Dorisio T.M., et al. Effect of somatostatin analog on peptide release and tumor growth in the Zollinger-Ellison syndrome. Surg Gynecol Obstet 1990, 170:474-484.
21. Mozell E.J., Cramer A.J. Long term efficacy of octreotide acetate in the treatment of Zollinger-Ellison syndrome. Arch Surg 1992, 127:1019-1026.
22. Shojamanesh H., Gibril F., Louie A., et al. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. Cancer 2002, 94(2):331-343.
23. Lyons J.M., Abergel J., Thomson J., et al. In vitro chemoresistance testing in well-differentiated carcinoid tumors. Ann Surg Oncol 2009, 16(3):649-655.
24. O'Toole D., Hentic O., Corcos O., et al. Chemotherapy for gastro-enteropancreatic endocrine tumors. Neuroendocrinology 2004, 80(Suppl 1):79-84.
25. Broder L.E., Carter S.K. Pancreatic islet cell carcinoma. results of therapy with streptozotocin in 52 patients. Ann Intern Med 1973, 79:108-118.
26. Baker J., Schnirer I.I., Yao J.C., et al. Phase II trial of irinotecan in patients with advanced carcinoid tumors. Proc Am Soc Clin Oncol 2002, 21:662.
27. Ansell S.M., Pitot H.C., Burch P.A., et al. A phase II study of high-dose paclitaxel in patients with advanced neoriendocrine tumors. Cancer 2001, 91:1543-1548.
28. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumors. Ann Oncol 2001, 12(Suppl 2):S111-S114.
29. Kolby L., Persson K.J., Franzen S., et al. Randomized control trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumors. Br J Surg 2003, 90:687-693.
30. Kwekkeboom D.J., Teunissen J.J.M., Kam B.L., et al. Treatment of patients who have endocrine gastroenteropancreatic tumors with radiolabeled somatostatin analogues. Hematol Oncol Clin North Am 2007, 21:561-573.
31. 3] octreotate in patients with gastroenteropancreatic (GEP) tumors. J Clin Oncol 2005, 23:2754-2762.
32. Nobels F.R., Kwekkeboom D.J., Coopmans W., et al. Chromogranin a as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997, 82:2622-2628.
33. Garrot C., Stuart K. Liver-directed therapies for metastatic neuroendocrine tumors. Hematol Oncol Clin North Am 2007, 21:545-560.
34. Ahlman H., Westbert G., Wangberg B., et al. Treatment of liver metastases of carcinoid tumors. World J Surg 1996, 20:196-202.
35. Norton J.A. Surgical treatment of neuroendocrine metastases. Best Pract Res Clin Gastroenterol 2005, 9(4):577-583.
36. Hellman P., Lundstrom T., Ohrvall U., et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastasis. World J Surg 2002, 26(8):991-997.
37. Que F.G., Nagorney D.M., Batts K.P., et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995, 169:36-42.
38. Givi B., Pommier S.J., Thompson A.K., et al. Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery 2006, 140:891-897.
39. Boudreaux J.P., Putty B., Frey D.J., et al. Surgical treatment of advanced-stage carcinoid tumors: lessons learned. Am Surg 2005, 241(6):839-845. [discussion: 845-6].
40. Wang Y.Z., Joseph S., Lindholm E., et al. Lymphatic mapping helps determine surgical margins in midgut carcinoids. Surgery 2009, 146(6):993-997.